Type 2 & other diabetes

Integrating inflammation, insulin resistance, and visceral adiposity: the C-reactive protein–triglyceride–glucose-Chinese visceral adiposity (CTI–Chinese visceral adiposity index (CVAI)) index is associated with cardiovascular disease risk across cardiovascular-kidney-metabolic (CKM) stages 0–3 in a nationwide prospective cohort

Cardiovasc DiabetolPublished Prospective cohort study

Authors' conclusion

CTI-CVAI is independently and linearly associated with incident CVD risk in Chinese adults with CKM stage 0-3. As a low-cost, accessible biomarker integrating three key pathological pathways, it optimizes early CVD risk stratification and reclassification, providing a promising tool for targeted CVD prevention in CKM high-risk populations.

Study context

Population
Chinese adults aged ≥45 years with CKM stages 0–3, China Health and Retirement Longitudinal Study
Participants
6,728 adults
Exposure
Higher vs lower CTI-CVAI
Outcome
Incident CVD
Follow-up
Median 9 years
Methodological detailsnationwide, China Health and Retirement Longitudinal Study (CHARLS) 2011-2020
  • Nationwide
  • CHARLS 2011-2020

Main finding

As reported in the abstract

Fully adjusted
Hazard ratio (95% CI)P value
Per 1-SD CTI-CVAI increment
1.32(1.26–1.39)
P < 0.001
Q4vs Q1
2.07(1.77–2.42)
P < 0.001
Overall cardiovascular disease (CVD) incidence
23.83%
Linear, dose-dependent association of CTI-CVAI with CVD risk
P < 0.001
Restricted cubic spline: linear association
P for non-linearity > 0.05

Observational data: associations, not effects.

Further findings

Risk reclassification vs single biomarkers

NRI
0.0566, P < 0.001

Subgroup and sensitivity analyses

Association stable across most subgroups; all sensitivity analyses robust

Original publication

Integrating inflammation, insulin resistance, and visceral adiposity: the C-reactive protein–triglyceride–glucose-Chinese visceral adiposity (CTI–CVAI) index is associated with cardiovascular disease risk across CKM stages 0–3 in a nationwide prospective cohort. Cardiovasc Diabetol. Published 12 June 2026. doi:10.1186/s12933-026-03248-3

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.